RA Capital is an evidence-based, multi-stage healthcare and planetary health investor and company builder inventing a healthier future.
AUM: $16.4B · Form ADV, 31 Mar 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: ASND | Current | Pharmaceutical Preparations | Common Stock | 10,281,496 | 0 | 0.0% | $2.3B | -$400M | 23.50% | $16.8B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PBLS | Current | Pharmaceutical Preparations | Common Stock | 29,177,964 | +244,593 | +0.8% | $942M | +$150M | 9.45% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PCVX | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 11,474,599 | 0 | 0.0% | 7.25% | $653M | -$14M | 6.55% | $9.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RYTM | Current | Pharmaceutical Preparations | Common Stock | 6,666,837 | 0 | 0.0% | 9.62% | $635M | -$105M | 6.37% | $8.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: EWTX | Current | Pharmaceutical Preparations | Common Stock | 8,392,730 | 0 | 0.0% | 7.67% | $341M | -$0.3M | 3.42% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: TYRA | Current | Pharmaceutical Preparations | Common Stock | 12,198,625 | 0 | 0.0% | 17.66% | $267M | -$123M | 2.68% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: FRNM | Current | Services-Medical Laboratories | Common Stock | 15,367,270 | +15,367,270 | New | 13.78% | $242M | +$242M | 2.43% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Hemab Therapeutics Holdings, Inc. | Nasdaq: COAG | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 7,808,627 | 0 | 0.0% | 16.71% | $241M | -$46M | 2.42% | $1.9B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Newamsterdam Pharma Company | Current | Common Stock | 9,883,524 | 0 | 0.0% | $236M | -$94M | 2.37% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: SEPN | Current | Pharmaceutical Preparations | Common Stock | 5,502,858 | -1,493,000 | -21.3% | 11.57% | $215M | -$19M | 2.16% | $1.9B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| SpyGlass Pharma, Inc. | Nasdaq: SGP | Current | Surgical & Medical Instruments & Apparatus | Common Stock | 8,021,117 | 0 | 0.0% | 23.97% | $209M | +$30M | 2.09% | $1.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: JANX | Current | Pharmaceutical Preparations | Common Stock | 11,189,693 | 0 | 0.0% | 18.29% | $193M | +$21M | 1.94% | $630M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MLYS | Current | Pharmaceutical Preparations | Common Stock | 7,692,750 | 0 | 0.0% | 8.69% | $193M | -$14M | 1.94% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRON | Current | Pharmaceutical Preparations | Common Stock | 2,450,221 | 0 | 0.0% | 5.38% | $160M | -$19M | 1.61% | $3.5B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TSHA | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 30,435,190 | +6,879,542 | +29.2% | 9.33% | $148M | -$12M | 1.49% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BCAX | Current | Pharmaceutical Preparations | Common Stock | 7,255,993 | 0 | 0.0% | 10.93% | $135M | -$80M | 1.35% | $605M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ARTV | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 18,489,293 | +533,651 | +3.0% | 37.40% | $132M | -$43M | 1.32% | $189M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: XNCR | Current | Pharmaceutical Preparations | Common Stock | 5,274,274 | 0 | 0.0% | 7.03% | $132M | +$47M | 1.32% | $2.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORKA | Current | Pharmaceutical Preparations | Common Stock | 1,554,597 | 0 | 0.0% | 2.29% | $129M | -$18M | 1.30% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: AMLX | Current | Pharmaceutical Preparations | Common Stock | 4,279,341 | +4,279,341 | New | 3.33% | $125M | +$125M | 1.25% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLYM | Current | Pharmaceutical Preparations | Common Stock | 10,130,130 | -1,170,809 | -10.4% | 17.25% | $116M | -$31M | 1.17% | $545M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ABVX | Current | Pharmaceutical Preparations | ADR | 1,030,058 | -102,499 | -9.1% | $102M | -$49M | 1.02% | $7.1B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Latigo Biotherapeutics, Inc. | Nasdaq: LTGO | Current | Pharmaceutical Preparations | Common Stock | 5,302,933 | +5,302,933 | New | 8.00% | $89M | +$89M | 0.89% | $878M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SLDB | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 12,036,126 | 0 | 0.0% | 10.78% | $87M | -$33M | 0.87% | $719M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Vor Biopharma Inc. | Nasdaq: VOR | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 4,503,882 | +2,101,787 | +87.5% | 7.33% | $86M | +$42M | 0.86% | $1.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| LB PHARMACEUTICALS INC | Nasdaq: LBRX | Current | Pharmaceutical Preparations | Common Stock | 2,208,604 | 0 | 0.0% | 6.82% | $85M | +$13M | 0.85% | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| GH Research PLC | Nasdaq: GHRS | Current | Pharmaceutical Preparations | Common Stock | 3,609,007 | -4,027,806 | -52.7% | $85M | -$121M | 0.85% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Obsidian Therapeutics, Inc. | Nasdaq: OBX | Current | Pharmaceutical Preparations | Common Stock | 5,957,103 | +5,957,103 | New | 9.64% | $82M | +$82M | 0.82% | $751M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ZLAB | Current | Pharmaceutical Preparations | ADR | 2,815,543 | -2,927,990 | -51.0% | $74M | -$35M | 0.74% | $2.7B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: FDMT | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 5,049,779 | 0 | 0.0% | $72M | +$5M | 0.72% | $604M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: ACRS | Current | Pharmaceutical Preparations | Common Stock | 12,723,026 | 0 | 0.0% | 8.02% | $67M | -$0.4M | 0.67% | $555M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SANA | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 18,750,000 | 0 | 0.0% | 6.26% | $55M | -$11M | 0.55% | $521M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MNPR | Current | Pharmaceutical Preparations | Common Stock | 667,207 | 0 | 0.0% | 9.85% | $53M | -$9M | 0.53% | $476M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: GERN | Current | Pharmaceutical Preparations | Common Stock | 42,754,145 | -55,606 | -0.1% | 6.64% | $53M | -$2M | 0.53% | $588M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PEPG | Current | Pharmaceutical Preparations | Common Stock | 20,064,545 | 0 | 0.0% | 28.97% | $49M | +$12M | 0.49% | $370M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SPRY | Current | Pharmaceutical Preparations | Common Stock | 10,860,977 | 0 | 0.0% | 10.80% | $47M | -$40M | 0.47% | $338M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Acumen Pharmaceuticals, Inc. | Nasdaq: ABOS | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 20,992,669 | 0 | 0.0% | 29.02% | $47M | -$9M | 0.47% | $14M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DBVT | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 3,657,644 | +3,657,644 | New | 1.16% | $43M | +$43M | 0.43% | $592M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AGEN | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 4,122,000 | +4,122,000 | New | 9.11% | $41M | +$41M | 0.41% | $278M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Rezolute, Inc. | Nasdaq: RZLT | Current | Pharmaceutical Preparations | Common Stock | 9,445,039 | 0 | 0.0% | 9.77% | $39M | -$10M | 0.39% | $499M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SION | Current | Pharmaceutical Preparations | Common Stock | 6,456,234 | -3,448,811 | -34.8% | 14.27% | $34M | -$402M | 0.34% | $134M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SCTX | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 1,802,178 | +1,802,178 | New | 9.52% | $33M | +$33M | 0.33% | $250M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IPSC | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 17,754,430 | 0 | 0.0% | 9.78% | $30M | -$13M | 0.30% | $240M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Evommune, Inc. | NYSE: EVMN | Current | Pharmaceutical Preparations | Common Stock | 3,494,638 | 0 | 0.0% | 8.45% | $29M | -$18M | 0.29% | $299M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Korsana Biosciences, Inc. | Nasdaq: KRSA | Current | Pharmaceutical Preparations | Common Stock | 892,743 | +892,743 | New | 1.96% | $29M | +$29M | 0.29% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | Common Stock | 3,014,183 | +1,506,339 | +99.9% | 5.18% | $29M | -$8M | 0.29% | $438M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: NKTX | Current | Pharmaceutical Preparations | Common Stock | 10,805,129 | 0 | 0.0% | 15.07% | $28M | -$2M | 0.28% | $80M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CCCC | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 8,194,779 | +194,779 | +2.4% | 6.24% | $27M | -$10M | 0.27% | $320M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: JBIO | Current | Pharmaceutical Preparations | Common Stock | 1,835,542 | -1,835,541 | -50.0% | 2.65% | $26M | -$56M | 0.26% | $1.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Prelude Therapeutics Inc | Nasdaq: PRLD | Current | Pharmaceutical Preparations | Common Stock | 6,475,882 | 0 | 0.0% | 8.09% | $25M | -$9M | 0.25% | $261M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Acrivon Therapeutics, Inc. | Nasdaq: ACRV | Current | Pharmaceutical Preparations | Common Stock | 12,229,396 | 0 | 0.0% | 28.50% | $25M | +$3M | 0.25% | $60M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| ASSEMBLY BIOSCIENCES, INC. | Nasdaq: ASMB | Current | Pharmaceutical Preparations | Common Stock | 1,020,410 | 0 | 0.0% | 4.98% | $24M | -$4M | 0.24% | $461M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: EDIT | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 8,889,000 | 0 | 0.0% | 5.76% | $23M | -$6M | 0.23% | $264M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Q32 Bio Inc. | Nasdaq: QTTB | Current | Pharmaceutical Preparations | Common Stock | 2,332,457 | 0 | 0.0% | 7.79% | $19M | -$10M | 0.19% | $254M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Anteris Technologies Global Corp. | Nasdaq: AVR | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | Common Stock | 2,474,076 | -525,924 | -17.5% | 2.54% | $19M | -$10M | 0.19% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ETRA | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 1,692,965 | +1,692,965 | New | 2.69% | $19M | +$19M | 0.19% | $561M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALT | Current | Pharmaceutical Preparations | Common Stock | 6,500,000 | 0 | 0.0% | 3.34% | $19M | -$1M | 0.19% | $274M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BNTC | Current | Pharmaceutical Preparations | Common Stock | 1,850,000 | 0 | 0.0% | 5.30% | $19M | -$6M | 0.19% | $294M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALXO | Current | Pharmaceutical Preparations | Common Stock | 13,011,849 | 0 | 0.0% | 10.07% | $18M | -$9M | 0.18% | $132M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SGMT | Current | Pharmaceutical Preparations | Common Stock | 1,800,000 | +1,800,000 | New | $18M | +$18M | 0.18% | $692M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Lexeo Therapeutics, Inc. | Nasdaq: LXEO | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 5,000,000 | 0 | 0.0% | 6.04% | $17M | -$6M | 0.17% | $244M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: LENZ | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 4,178,823 | 0 | 0.0% | 13.30% | $16M | -$8M | 0.16% | $105M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Aura Biosciences, Inc. | Nasdaq: AURA | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 2,500,000 | 0 | 0.0% | 2.40% | $16M | -$2M | 0.16% | $726M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: AVTX | Current | Pharmaceutical Preparations | Common Stock | 1,000,000 | 0 | 0.0% | 1.73% | $15M | -$3M | 0.15% | $390M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Inhibikase Therapeutics, Inc. | Nasdaq: IKT | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 6,970,000 | +6,970,000 | New | 4.97% | $14M | +$14M | 0.14% | $182M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Entera Bio Ltd. | Nasdaq: ENTX | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 4,901,960 | +4,901,960 | New | 2.81% | $14M | +$14M | 0.14% | $571M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Seaport Therapeutics, Inc. | Nasdaq: SPTX | Current | Pharmaceutical Preparations | Common Stock | 700,000 | 0 | 0.0% | 1.31% | $14M | -$1M | 0.14% | $981M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| SAB Biotherapeutics, Inc. | Nasdaq: SABS | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 4,401,500 | 0 | 0.0% | 4.89% | $14M | -$3M | 0.14% | $262M | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 |
| Ovid Therapeutics Inc. | Nasdaq: OVID | Current | Pharmaceutical Preparations | Common Stock | 5,598,200 | -4,902,768 | -46.7% | 2.97% | $14M | -$14M | 0.14% | $442M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: MIRM | Current | Pharmaceutical Preparations | Common Stock | 159,278 | -159,276 | -50.0% | 0.24% | $14M | -$24M | 0.14% | $6.2B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Helix Acquisition Corp. III | Nasdaq: HLXC | Current | Blank Checks | Common Stock | 1,250,000 | 0 | 0.0% | $13M | -$0.0M | 0.13% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: DRUG | Current | Pharmaceutical Preparations | Common Stock | 265,000 | 0 | 0.0% | $13M | -$5M | 0.13% | $204M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CRBP | Current | Pharmaceutical Preparations | Common Stock | 1,914,788 | +1,914,788 | New | 9.29% | $13M | +$13M | 0.13% | $50M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Braveheart Bio, Inc. | Nasdaq: BRVE | Current | Pharmaceutical Preparations | Common Stock | 565,000 | +565,000 | New | 0.63% | $11M | +$11M | 0.11% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| OnKure Therapeutics, Inc. | Nasdaq: OKUR | Current | Pharmaceutical Preparations | Common Stock | 3,998,333 | 0 | 0.0% | 9.87% | $11M | -$7M | 0.11% | $114M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| PALISADE BIO, INC. | Nasdaq: PALI | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 7,124,116 | 0 | 0.0% | 3.97% | $10M | -$5M | 0.10% | $166M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: INO | Current | Pharmaceutical Preparations | Common Stock | 7,220,384 | +7,220,384 | New | 3.85% | $9M | +$9M | 0.09% | $320M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| MACROGENICS INC | Nasdaq: MGNX | Current | Pharmaceutical Preparations | Common Stock | 1,864,176 | 0 | 0.0% | 2.92% | $7M | -$1M | 0.07% | $127M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Rani Therapeutics Holdings, Inc. | Nasdaq: RANI | Current | Pharmaceutical Preparations | Common Stock | 8,500,000 | 0 | 0.0% | $7M | +$0.3M | 0.07% | $67M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Adicet Bio, Inc. | Nasdaq: ACET | Current | Pharmaceutical Preparations | Common Stock | 932,624 | 0 | 0.0% | 9.96% | $7M | -$1M | 0.07% | $23M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| TCGX Acquisition Corp. | Nasdaq: TCGX | Current | Blank Checks | Common Stock | 500,000 | +500,000 | New | $6M | +$6M | 0.06% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Faeth Therapeutics, Inc. | Nasdaq: FTH | Current | Pharmaceutical Preparations | Common Stock | 205,060 | -516,960 | -71.6% | 0.79% | $6M | -$12M | 0.06% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| JATT II Acquisition Corp. | Nasdaq: JATT | Current | Blank Checks | Common Stock | 500,000 | 0 | 0.0% | 6.41% | $6M | -$0.1M | 0.06% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| JATT III Acquisition Corp | Nasdaq: JTTT | Current | Blank Checks | Common Stock | 450,000 | +450,000 | New | 5.08% | $5M | +$5M | 0.05% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Amanat Acquisition Corp | Current | Common Stock | 375,000 | 0 | 0.0% | $4M | +$0.2M | 0.04% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Equillium, Inc. | Nasdaq: EQ | Current | Pharmaceutical Preparations | Common Stock | 2,317,741 | -778,595 | -25.1% | 2.82% | $4M | -$6M | 0.04% | $92M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: STRO | Current | Biological Products, (No Diagnostic Substances) | Common Stock | 210,934 | +210,934 | New | 1.27% | $3M | +$3M | 0.03% | $145M | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | Common Stock | 73,607 | +73,607 | New | 0.11% | $2M | +$2M | 0.02% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| PALATIN TECHNOLOGIES INC | Nasdaq: PTN | Current | Pharmaceutical Preparations | Common Stock | 62,124 | 0 | 0.0% | 3.49% | $0.6M | -$0.1M | 0.01% | $9M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 |
| Ascendis Pharma A/S Sponsored ADR | Exited | SPONSORED ADR | 0 | -10,281,496 | -100.0% | -$2.4B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||||
| Cidara Therapeutics, Inc. | Exited | SH | 0 | -3,365,523 | -100.0% | -$743M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Avidity Biosciences Inc | Exited | SH | 0 | -8,641,031 | -100.0% | -$623M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| 89bio Inc | Exited | SH | 0 | -19,889,683 | -100.0% | -$292M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: LEGN | Exited | Pharmaceutical Preparations | SH | 0 | -7,506,934 | -100.0% | -$244M | $3.1B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: BIIB | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,184,456 | -100.0% | -$230M | $36.5B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Dianthus Therapeutics, Inc. /DE/ | Nasdaq: DNTH | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -2,611,733 | -100.0% | -$219M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: BCRX | Exited | Biological Products, (No Diagnostic Substances) | Common Stock | 0 | -15,827,186 | -100.0% | -$158M | $1.9B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: WVE | Exited | Pharmaceutical Preparations | Common Stock | 0 | -26,975,505 | -100.0% | -$157M | $536M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Nuvalent Inc | Exited | Common Stock | 0 | -1,246,456 | -100.0% | -$154M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Nasdaq: PRAX | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -373,787 | -100.0% | -$120M | $8.7B | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Spdr S&p Biotech Etf | Exited | Fund | SH | 0 | -1,228,240 | -100.0% | -$111M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||||
| Nasdaq: DYN | Exited | Pharmaceutical Preparations | SH | 0 | -9,714,392 | -100.0% | -$92M | $3.0B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: SRPT | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -3,902,596 | -100.0% | -$85M | $1.5B | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: AXSM | Exited | Pharmaceutical Preparations | SH | 0 | -1,000,000 | -100.0% | -$85M | $7.1B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Arcellx | Exited | SH | 0 | -1,267,156 | -100.0% | -$83M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Verona Pharma PLC | Exited | SH | 0 | -1,766,830 | -100.0% | -$82M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Spyre Therapeutics, Inc. | Nasdaq: SYRE | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -1,621,620 | -100.0% | -$82M | $9.3B | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: NTLA | Exited | In Vitro & In Vivo Diagnostic Substances | Common Stock | 0 | -4,526,926 | -100.0% | -$77M | $1.3B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: DFTX | Exited | Medicinal Chemicals & Botanical Products | Common Stock | 0 | -1,500,000 | -100.0% | -$71M | $4.0B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: BLTE | Exited | Pharmaceutical Preparations | SH | 0 | -432,484 | -100.0% | -$69M | $6.1B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: DMRA | Exited | Pharmaceutical Preparations | Common Stock | 0 | -2,399,702 | -100.0% | -$62M | $1.5B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Apogee Therapeutics Inc | Exited | SH | 0 | -1,569,491 | -100.0% | -$59M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: CGON | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,397,433 | -100.0% | -$53M | $7.3B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: RXRX | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -7,725,096 | -100.0% | -$52M | $1.7B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: RXST | Exited | Ophthalmic Goods | SH | 0 | -3,702,967 | -100.0% | -$48M | $193M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: FULC | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -6,053,960 | -100.0% | -$46M | $283M | Q2 2026 | 14 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Day One Biopharmaceuticals Inc | Exited | SH | 0 | -5,755,577 | -100.0% | -$46M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: SRRK | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,166,788 | -100.0% | -$43M | $6.1B | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: GPCR | Exited | Pharmaceutical Preparations | SH | 0 | -1,517,418 | -100.0% | -$42M | $1.2B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: AKTS | Exited | Pharmaceutical Preparations | Common Stock | 0 | -1,314,405 | -100.0% | -$42M | $915M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Nasdaq: IVVD | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -17,119,096 | -100.0% | -$42M | $132M | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: BIOA | Exited | Pharmaceutical Preparations | Common Stock | 0 | -1,671,648 | -100.0% | -$41M | $216M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||
| Tourmaline Bio Inc | Exited | SH | 0 | -2,538,925 | -100.0% | -$41M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: OLMA | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -2,600,000 | -100.0% | -$39M | $626M | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: URGN | Exited | Pharmaceutical Preparations | SH | 0 | -3,206,271 | -100.0% | -$35M | $1.6B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| Metsera Inc | Exited | SH | 0 | -675,525 | -100.0% | -$35M | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Design Therapeutics, Inc. | Nasdaq: DSGN | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -2,972,973 | -100.0% | -$32M | $597M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Chimerix Inc | Exited | SH | 0 | -8,800,000 | -100.0% | -$31M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Astria Therapeutics Inc | Exited | SH | 0 | -5,105,213 | -100.0% | -$27M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nasdaq: KURA | Exited | Pharmaceutical Preparations | SH | 0 | -4,004,610 | -100.0% | -$26M | $675M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: ANRO | Exited | Pharmaceutical Preparations | SH | 0 | -2,075,154 | -100.0% | -$24M | $1.1B | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||
| Nasdaq: TVTX | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -746,841 | -100.0% | -$22M | $4.6B | Q2 2026 | 14 Aug 2026 | Q4 2024 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: GRAL | Exited | Services-Medical Laboratories | COMMON STOCK | 0 | -428,266 | -100.0% | -$22M | $4.5B | Q2 2026 | 14 Aug 2026 | Q4 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: IDYA | Exited | Pharmaceutical Preparations | SH | 0 | -1,347,252 | -100.0% | -$22M | $2.5B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Iteos Therapeutics Inc | Exited | SH | 0 | -3,649,057 | -100.0% | -$22M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| RELMADA THERAPEUTICS, INC. | Nasdaq: RLMD | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -2,947,369 | -100.0% | -$21M | $332M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| Nasdaq: LRMR | Exited | Pharmaceutical Preparations | SH | 0 | -6,045,351 | -100.0% | -$20M | $337M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Karyopharm Therapeutics Inc | KPTIQ | Exited | Common Stock | 0 | -1,917,354 | -100.0% | -$19M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | |||||
| EyePoint, Inc. | Nasdaq: EYPT | Exited | Laboratory Analytical Instruments | SH | 0 | -3,181,818 | -100.0% | -$17M | $30M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: ELVN | Exited | Pharmaceutical Preparations | SH | 0 | -848,986 | -100.0% | -$17M | $3.4B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: CTNM | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -1,296,012 | -100.0% | -$17M | $355M | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: PLRX | Exited | Pharmaceutical Preparations | SH | 0 | -1,281,000 | -100.0% | -$17M | $38M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: TNGX | Exited | Pharmaceutical Preparations | SH | 0 | -2,000,000 | -100.0% | -$17M | $3.8B | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| NYSE: INSP | Exited | Surgical & Medical Instruments & Apparatus | COMMON STOCK | 0 | -325,663 | -100.0% | -$17M | $1.6B | Q2 2026 | 14 Aug 2026 | Q3 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| Nasdaq: PRME | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -3,000,000 | -100.0% | -$17M | $856M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: CBLL | Exited | Electromedical & Electrotherapeutic Apparatus | SH | 0 | -824,582 | -100.0% | -$16M | $1.0B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: NRIX | Exited | Pharmaceutical Preparations | SH | 0 | -1,333,333 | -100.0% | -$16M | $1.5B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: RCUS | Exited | Pharmaceutical Preparations | SH | 0 | -1,136,364 | -100.0% | -$15M | $2.3B | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: INSM | Exited | Pharmaceutical Preparations | SH | 0 | -200,000 | -100.0% | -$15M | $31.7B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Medline Inc. | Nasdaq: MDLN | Exited | Surgical & Medical Instruments & Apparatus | SH | 0 | -335,000 | -100.0% | -$14M | $49.8B | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | |||
| NYSE: HNGE | Exited | Services-Computer Processing & Data Preparation | COMMON STOCK | 0 | -364,613 | -100.0% | -$14M | $8.8B | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | ||||
| GeneDx Holdings Corp. | Nasdaq: WGS | Exited | Services-Health Services | COMMON STOCK | 0 | -209,887 | -100.0% | -$13M | $1.5B | Q2 2026 | 14 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Tenaya Therapeutics, Inc. | Nasdaq: TNYA | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -6,982,587 | -100.0% | -$13M | $68M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| CervoMed Inc. | Nasdaq: CRVO | Exited | Pharmaceutical Preparations | SH | 0 | -817,120 | -100.0% | -$12M | $20M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Nasdaq: ALEC | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -9,695,228 | -100.0% | -$12M | $342M | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Uniqure NV | Exited | SH | 0 | -200,000 | -100.0% | -$12M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Atrium Therapeutics, Inc. | Nasdaq: RNA | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -864,102 | -100.0% | -$12M | $151M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| SERA PROGNOSTICS, INC. | Nasdaq: SERA | Exited | Services-Medical Laboratories | SH | 0 | -3,032,808 | -100.0% | -$11M | $75M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Nasdaq: WAY | Exited | Services-Computer Integrated Systems Design | Common Stock | 0 | -529,400 | -100.0% | -$11M | $5.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q2 2026 | 13F, Q2 2026 | ||||
| Third Harmonic Bio Inc | Exited | SH | 0 | -960,620 | -100.0% | -$10M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Nasdaq: BCYC | Exited | Pharmaceutical Preparations | SH | 0 | -1,093,477 | -100.0% | -$9M | $214M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Eledon Pharmaceuticals, Inc. | Nasdaq: ELDN | Exited | Pharmaceutical Preparations | SH | 0 | -3,566,338 | -100.0% | -$9M | $160M | Q4 2025 | 17 Feb 2026 | Q4 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: CTMX | Exited | Pharmaceutical Preparations | SH | 0 | -2,661,331 | -100.0% | -$8M | $447M | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| Perceptive Cap Solutions Cor | Exited | Common Stock | 0 | -750,000 | -100.0% | -$8M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Nasdaq: ARVN | Exited | Pharmaceutical Preparations | SH | 0 | -421,348 | -100.0% | -$8M | $441M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: IMTX | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,750,000 | -100.0% | -$8M | $906M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Surrozen, Inc./DE | Nasdaq: SRZN | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -602,626 | -100.0% | -$8M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Nasdaq: OMDA | Exited | Services-Health Services | SH | 0 | -400,000 | -100.0% | -$7M | $775M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: BBNX | Exited | Surgical & Medical Instruments & Apparatus | SH | 0 | -500,000 | -100.0% | -$7M | $724M | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: CRVS | Exited | Pharmaceutical Preparations | Common Stock | 0 | -450,000 | -100.0% | -$7M | $844M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| ENANTA PHARMACEUTICALS INC | Nasdaq: ENTA | Exited | Pharmaceutical Preparations | SH | 0 | -1,038,000 | -100.0% | -$6M | $232M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Humacyte, Inc. | Nasdaq: HUMA | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -3,312,356 | -100.0% | -$6M | $151M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | |||
| 10x Genomics, Inc. | Nasdaq: TXG | Exited | Laboratory Analytical Instruments | SH | 0 | -475,343 | -100.0% | -$6M | $7.5B | Q3 2025 | 14 Nov 2025 | Q4 2024 | Q2 2025 | 13F, Q2 2025 | |||
| MapLight Therapeutics, Inc. | Nasdaq: MPLT | Exited | Pharmaceutical Preparations | COMMON STOCK | 0 | -248,294 | -100.0% | -$5M | $357M | Q2 2026 | 14 Aug 2026 | Q1 2026 | Q1 2026 | 13F, Q1 2026 | |||
| Evolent Health, Inc. | NYSE: EVH | Exited | Services-Management Services | SH | 0 | -579,052 | -100.0% | -$5M | $388M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| NYSE: GKOS | Exited | Surgical & Medical Instruments & Apparatus | SH | 0 | -54,180 | -100.0% | -$4M | $14.1B | Q4 2025 | 17 Feb 2026 | Q1 2025 | Q3 2025 | 13F, Q3 2025 | ||||
| MBX Biosciences, Inc. | Nasdaq: MBX | Exited | Pharmaceutical Preparations | SH | 0 | -377,841 | -100.0% | -$4M | $2.7B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Zura Bio Ltd | Nasdaq: ZURA | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -3,217,503 | -100.0% | -$4M | $92M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Adagio Med Hldgs Inc | Exited | SH | 0 | -1,333,926 | -100.0% | -$3M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Nasdaq: BOLD | Exited | Pharmaceutical Preparations | SH | 0 | -2,180,631 | -100.0% | -$3M | $56M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: TARA | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,039,295 | -100.0% | -$3M | $148M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Exact Sciences Corp | Exited | SH | 0 | -54,939 | -100.0% | -$3M | Q4 2025 | 17 Feb 2026 | Q3 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Metagenomi Therapeutics, Inc. | Nasdaq: MGX | Exited | Biological Products, (No Diagnostic Substances) | SH | 0 | -1,305,239 | -100.0% | -$3M | $23M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Inflarx NV | Exited | SH | 0 | -1,973,233 | -100.0% | -$3M | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: PGNY | Exited | Services-Misc Health & Allied Services, NEC | SH | 0 | -96,628 | -100.0% | -$2M | $2.6B | Q1 2026 | 15 May 2026 | Q3 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| AN2 Therapeutics, Inc. | Nasdaq: ANTX | Exited | Pharmaceutical Preparations | SH | 0 | -1,999,997 | -100.0% | -$2M | $198M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Qiagen NV | Exited | SH | 0 | -43,976 | -100.0% | -$2M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: ACHC | Exited | Services-Specialty Outpatient Facilities, NEC | SH | 0 | -89,262 | -100.0% | -$2M | $3.2B | Q3 2025 | 14 Nov 2025 | Q1 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: KIDS | Exited | Surgical & Medical Instruments & Apparatus | SH | 0 | -109,959 | -100.0% | -$2M | $849M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: HCAT | Exited | Services-Computer Programming, Data Processing, Etc. | SH | 0 | -793,749 | -100.0% | -$2M | $98M | Q1 2026 | 15 May 2026 | Q4 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Allakos Inc | Exited | SH | 0 | -1,129,931 | -100.0% | -$1M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Werewolf Therapeutics, Inc. | Nasdaq: HOWL | Exited | Pharmaceutical Preparations | Common Stock | 0 | -2,387,744 | -100.0% | -$0.9M | $48M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | |||
| Regulus Therapeutics Inc | Exited | SH | 0 | -336,843 | -100.0% | -$0.5M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Scilex Holding Co | Exited | SH | 0 | -1,036,218 | -100.0% | -$0.3M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 |
Adam KayeSenior Managing Director and Partner, Structured Capital · Present
Alden MastersHuman Resources Business Partner · Present
Alison TisdaleVenture Partner · Present
Anish SuriConsulting Venture Partner · Present
Anurag KondapalliPrincipal · Present
Cassie HoffmanTechnology Business Partner - Business Operations · Present
Charlotte McDonaghVenture Partner · Present
Chris KozielAssociate Wealth Advisor, Family Office and Partner Services · Present
Chris MorrisonOperations Associate, Family Office and Partner Services · Present
Colleen ShieldsBusiness Technology Partner · Present
Derek DiRoccoPartner · Present
Fuad NaserManaging Director, Venture · Present
Gerald SewackVenture Partner · Present
Henry StusnickManaging Director, Venture · Present
Jaclyn HendersonVenture Partner · Present
Jacob OppenheimVenture Partner · Present
Jake SimsonPartner · Present
Jill WykoskyVenture Partner · Present
Kara GallagherTax Associate, Family Office and Partner Services · Present
Kate McKennaHuman Resources Business Partner · Present
Kathryn MengPrincipal · Present
Kleem ChaudharyVenture Partner · Present
Kyle TeameyManaging Partner · Present
Laura StoppelPartner · Present
Laura TadvalkarManaging Director, Venture · Present
Lauren MitsiarisOperations Associate, Family Office and Partner Services · Present
Le HoTechnology Business Partner - Business Operations · Present
Mario BarroVenture Partner · Present
Matthew FerestenTechnology Business Partner - Invest · Present
Milind DeshpandeVenture Partner · Present
Nandita ShangariManaging Director, Venture · Present
Nithya DesikanVenture Partner · Present
Paul YaworskyVenture Partner · Present
Peter BaloghSenior Managing Director and Partner, Structured Capital · Present
Peter KolchinskyManaging Partner · Present
Rajeev ShahManaging Partner · Present
Robert NicolVenture Partner · Present
Stacey LynchTalent Operations Business Partner · Present
Tess CameronManaging Director, Venture · Present
Tyler CarneyManaging Director, Venture · Present
Zach ScheinerPartner · Present